Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 679 of 5804
-
New targeted pill shows promise for Hard-to-Treat lung cancer
Disease control TerminatedThe main objective of this study is to evaluate the tumor objective response rate (ORR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in participants who receive sotorasib at either 960 mg daily or 240 mg daily whose tumors are programmed death-li…
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug combo shows promise for Tough-to-Treat endometrial cancer
Disease control CompletedThe purpose of this study is to find out whether the combination of pembrolizumab and olaparib is an effective treatment for people with persistent or recurrent endometrial cancer or endometrial carcinosarcoma. The researchers will also look at the safety of the drug combination …
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug combo offers hope for rare Pregnancy-Related cancer
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of camrelizumab and apatinib as combination therapy in patients with ultra high-risk (Cohort A) and high-risk chemo-refractory or relapsed (Cohort B) gestational trophoblastic neoplasia (GTN). Eligible patients will…
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Immunotherapy drug shows promise before colon cancer surgery
Disease control CompletedThe main purpose of this study was to help meet the medical needs of people in China with certain types of solid tumors that have specific genetic changes called microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR). The study looked at how well the drug tis…
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo aims to extend life in tough lung cancer
Disease control Recruiting nowThis phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Chemotherapy drugs, such as temozolomide, wor…
Phase: PHASE2 • Sponsor: Dwight Owen • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo therapy aims to wipe out esophageal cancer before surgery
Disease control OngoingThis phase II trial studies the effect of chemoradiation and pembrolizumab followed by pembrolizumab and lenvatinib before surgery in treating patients with esophageal or esophageal/gastroesophageal junction cancer that has not spread to other places in the body (non-metastatic).…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Engineered immune cells take on childhood cancers that Won't quit
Disease control TerminatedThis phase I trial investigates the side effects and determines the best dose of an immune cell therapy called GD2CART, as well as how well it works in treating patients with osteosarcoma or neuroblastoma that has come back (relapsed) or does not respond to treatment (refractory)…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New immune drug STK-012 takes on tough lung cancers
Disease control Recruiting nowThis is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combinati…
Phase: PHASE1, PHASE2 • Sponsor: Synthekine • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat prostate cancer
Disease control CompletedThe purpose of this study is to assess the efficacy, tolerability, safety, pharmacokinetic (PK) and dosimetry of 177Lu-PSMA-617, in participants with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in Japan. F…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New Two-Punch strategy aims to control aggressive prostate cancer
Disease control OngoingThe goal of this clinical research is to find if sequential therapy with combined androgen deprivation or hormonal therapy with luteinizing hormone release hormone (LHRH) analog plus a new hormonal agent (abiraterone, enzalutamide, or apalutamide) followed by chemohormonal therap…
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Immunotherapy duo shows promise against rare lung cancer in chinese trial
Disease control CompletedThe purpose of this study is to assess the efficacy and safety of the combination of nivolumab and ipilimumab in Chinese participants with malignant pleural mesothelioma.
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can a monthly injection stop MS in its tracks? new study aims to find out
Disease control CompletedThis study evaluates the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes. The study also assesses changes in disease using monitoring…
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Proton beam offers new hope for recurrent tumors
Disease control Recruiting nowThe goal of this clinical research trial is to study the use of differing investigational doses and scheduling for Proton Therapy for tumors previously treated with radiation therapy. Generally, when patients are first treated for cancer with radiation therapy, they are treated w…
Phase: NA • Sponsor: The New York Proton Center • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug cocktail shows promise against tough cancers
Disease control CompletedPhase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117(Anti-CD47 Antibody)with or without chemotherapy in advanced malignant tumors
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
App aims to slash HIV rates in young transgender women
Prevention OngoingThe LifeSkills Mobile app will be evaluated in a randomized controlled trial (RCT) among 5,000 young transgender women (YTW), ages 16-29 in the United States (U.S.). Study findings will demonstrate if the intervention will reduce HIV incidence.
Phase: NA • Sponsor: University of California, Los Angeles • Aim: Prevention
Last updated Jun 27, 2026 12:02 UTC
-
New granule drug could ease tumors in toddlers with NF1
Disease control OngoingThis study is designed to define a dosing regimen and assess the pharmacokinetics(PK) and safety of the granule formulation; the study will also include descriptive analyses of exploratory efficacy endpoints. The study will inform the benefit risk profile of the granule formulati…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for brain metastases? drug combo trial opens
Disease control Recruiting nowThis is a single-center, open-label, multi-cohort Phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with solid tumors and brain metastases. The study will be comprised of 3 patient cohorts: triple negative breast cancer…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New study tests which treatment is best for pelvic bone cancers
Disease control Recruiting nowThis study compares carbon ion therapy, surgery, and proton therapy to determine if one has better disease control and fewer side effects. There are three types of radiation treatment used for pelvic bone sarcomas: surgery with or without photon/proton therapy, proton therapy alo…
Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug guselkumab aims to tame Crohn's Flare-Ups
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New combo therapy aims to stall lung cancer progression
Disease control OngoingIn this study, patients with metastatic non-small cell lung cancer that is EGFR-mutated, who have received at least 8 and not more than 12 weeks of treatment with osimertinib without demonstrating disease progression, will receive APL-101 in combination with osimertinib until pro…
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC